Dr. Frédéric Calon is a Professor at the Faculty of Pharmacy and principal investigator at the Centre de recherche du CHU de Québec-Laval University since 2003. He is a biochemist-pharmacist focusing his research program on the development of treatments for neurodegenerative diseases.

Author of more than 120 peer-reviewed articles, he and his team at Laval University, Quebec City, mainly carry on preclinical assays in animal models of brain diseases or neuropathology studies on human brain samples. His fields of expertise are focused on neurodegenerative diseases (Alzheimer’s and Parkinson’s), essential tremor, as well as general neuropharmacology. Dr. Calon is mostly known for his contribution to the discovery of a neuroprotective effect of omega-3 fatty acids in animal models of Alzheimer’s disease, Parkinson’s disease, and ischemic stroke. He cofounded with Sophie Layé (Bordeaux) in 2014 the Laboratoire International Associé (LIA) OptiNutriBrain, a unique collaborative laboratory now one of the world references in research on nutrition and brain diseases.

Dr. Calon’s group has also contributed to the discoveries of neuropathological clues in the cerebellum of patients that had suffered from essential tremor.

Finally, Dr. Calon’s team has developed a unique research platform to quantitatively and qualitatively the capacity of drugs to cross the blood-brain barrier, which is now the limiting step in CNS drug development.

His discoveries have been the subject of hundreds of public reports (radio, TV, and written press) and were highlighted by major national and international media. These discoveries have attracted considerable public interest and media coverage, including prime time interviews for Radio-Canada (TV, radio, internet) and the front page of the Globe and Mail. Dr. Calon’s work on GABA receptors in ET was selected among the top 10 scientific discoveries made in Quebec in 2012 and featured on “Le code Chastenay” on Télé-Québec, and he was also chosen as one of the “Lauréats de Québec LeSoleil/Radio-Canada” (personalities of the week) in 2013. In addition, one of his latest discoveries was published in Paris Match in 2015.

The goal of Dr. Calon’s work is to accelerate the transfer of knowledge from basic neuroscience to clinical applications for CNS diseases.

2705, boulevard Laurier
Québec, Québec
Canada G1V 4G2
144 entries « 1 of 29 »

St-Amour I, Bosoi CR, Pare I, Ignatius Arokia Doss PM, Rangachari M, Hebert SS, Bazin R, Calon F

Peripheral adaptive immunity of the triple transgenic mouse model of Alzheimer's disease.

Journal Article

J Neuroinflammation, 16 (1), pp. 3, 2019.

Abstract | Links:

Bourassa P, Alata W, Tremblay C, Paris-Robidas S, Calon F

Transferrin receptor-mediated uptake at the blood-brain barrier is not impaired by Alzheimer's disease neuropathology.

Journal Article

Mol Pharm, 2019, ISSN: 1543-8384.

Abstract | Links:

Boutin S, Roy J, Maltais R, Alata W, Calon F, Poirier D

Identification of steroidal derivatives inhibiting the transformations of allopregnanolone and estradiol by 17β-hydroxysteroid dehydrogenase type 10.

Journal Article

Bioorg Med Chem Lett, 28 (22), pp. 3554-3559, 2018, ISSN: 0960-894X.

Abstract | Links:

Thammisetty SS, Pedragosa J, Weng YC, Calon F, Planas A, Kriz J

Age-related deregulation of TDP-43 after stroke enhances NF-κB-mediated inflammation and neuronal damage.

Journal Article

J Neuroinflammation, 15 (1), pp. 312, 2018.

Abstract | Links:

Wang X, Liu D, Huang HZ, Wang ZH, Hou TY, Yang X, Pang P, Wei N, Zhou YF, Dupras MJ, Calon F, Wang YT, Man HY, Chen JG, Wang JZ, Hebert SS, Lu Y, Zhu LQ

A Novel MicroRNA-124/PTPN1 Signal Pathway Mediates Synaptic and Memory Deficits in Alzheimer's Disease.

Journal Article

Biol Psychiatry, 83 (5), pp. 395-405, 2018, ISSN: 0006-3223.

Abstract | Links:

144 entries « 1 of 29 »

Active projects

  • Centre de recherche en endocrinologie, métabolisme et inflammation, Subvention, Institutionnel - BDR, BDR - Centres de recherche reconnus, from 1996-06-01 to 2023-04-30
  • Centre hospitalier universitaire de Québec - CHU de Québec-Université Laval, Subvention, Centre hospitalier universitaire de Québec - Université Laval, Centres de recherche affiliés, from 2017-01-01 to 2099-12-31
  • Centre thématique de recherche en neurosciences, Subvention, Institutionnel - BDR, BDR - Centres de recherche reconnus, from 1999-06-01 to 2020-10-18
  • Clinicopathological Investigations of the substantia nigra in Parkinson's disease, Subvention, Société Parkinson Canada, Pilot Project Grant, from 2017-07-01 to 2019-06-30
  • Institut sur la nutrition et les aliments fonctionnels (INAF), Subvention, Fonds de recherche du Québec - Nature et technologies, Regroupements stratégiques, from 2017-04-01 to 2023-03-31
  • Institut sur la nutrition et les aliments fonctionnels, Subvention, Institutionnel - BDR, Instituts reconnus, from 2001-06-01 to 2019-04-30
  • Institut sur le vieillissement et la participation sociale des aînés, Subvention, Institutionnel - BDR, Instituts reconnus, from 2002-06-01 to 2019-04-30
  • Investigating the contribution of Shank3 in Alzheimer's disease, Subvention, Instituts de recherche en santé du Canada, Subvention Projet, from 2018-04-01 to 2023-03-31
  • Laboratoire international associé (LIA) OptiNutriBrain, Subvention, Institutionnel - BDR, Laboratoire international associé (LIA), from 2015-03-01 to 2020-03-01
  • The role of ApoE genotype on blood-brain barrier functions, Subvention, Conseil de recherches en sciences naturelles et génie Canada, Subventions à la découverte SD (individuelles et d'équipe), from 2013-04-01 to 2019-03-31

Recently finished projects

  • 3.8 Deciphering host-microbial interactions for cardiometabolic and mental health disorders with novel multimodal light-based sensing tools, Subvention, Secrétariat des programmes interorganismes à l’intention des établissements, Fonds d'excellence en recherche Apogée Canada, from 2016-04-01 to 2018-03-31
  • Agent de livraison de protéines in vivo, Partenariat, Conseil de recherches en sciences naturelles et génie Canada, Programme de subvention d'engagement partenarial (SEP), from 2016-11-01 to 2017-04-30
  • Approches pharmaceutiques, nutraceutiques et immunologiques pour le traitement des maladies neurodégénératives, Subvention, Fonds de recherche du Québec - Santé, Chercheur-boursier Juniors 1 et 2, Seniors, from 2013-07-01 to 2017-06-30
  • Causal relationship between a LC-0mega-3-enriched diet and cognition, Subvention, Instituts de recherche en santé du Canada, Subvention de fonctionnement, from 2012-01-01 to 2017-03-31
  • Ciblage de la barrière hémato-encéphalique pour traiter les maladies neurodégénératives, Partenariat, Fondation Canadienne pour l'innovation (La), Fonds des leaders John-R.-Evans (FLJR), from 2015-08-01 to 2017-06-30
  • Development and bioimaging of blood-brain barrier vectorized nanoparticles, Partenariat, Instituts de recherche en santé du Canada, Subvention de fonctionnement : Projets de recherche concertée sur la santé (partenariat avec CRSNG), from 2013-04-01 to 2016-09-30
  • Does a thermoregulatory deficit contribute to AD?, Subvention, Société Alzheimer du Canada, Subventions de recherche, from 2014-09-01 to 2016-08-31
  • Impact d'une carence en Omega-3 sur le développement cérébral dépendant de la microglie, Subvention, Fonds de recherche du Québec - Nature et technologies, Programme de développement de partenariats stratégiques en matière d’enseignement et de recherche, from 2016-04-01 to 2018-03-31
  • Is there a cerebellar accumulation of amyloid beta peptides in essential tremor., Subvention, Association des personnes concernées par le tremblement essentiel, from 2014-10-08 to 2016-04-07
  • Targeted delivery into brain capillary endothelial cells for the treatment of Alzheimer disease, Subvention, Instituts de recherche en santé du Canada, Subvention de fonctionnement, from 2013-01-01 to 2018-03-31
Data provided by the Université Laval research projects registery